Mirae Asset Global Investments Co. Ltd. Sells 22,532 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Mirae Asset Global Investments Co. Ltd. trimmed its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 37.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 38,187 shares of the biopharmaceutical company’s stock after selling 22,532 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Alnylam Pharmaceuticals were worth $7,340,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Norges Bank purchased a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $240,703,000. Wellington Management Group LLP lifted its holdings in shares of Alnylam Pharmaceuticals by 6.0% during the third quarter. Wellington Management Group LLP now owns 6,431,814 shares of the biopharmaceutical company’s stock valued at $1,139,074,000 after purchasing an additional 364,021 shares during the last quarter. Eaton Vance Management lifted its holdings in shares of Alnylam Pharmaceuticals by 606.7% during the first quarter. Eaton Vance Management now owns 306,228 shares of the biopharmaceutical company’s stock valued at $50,005,000 after purchasing an additional 262,893 shares during the last quarter. Ameriprise Financial Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 328.9% during the first quarter. Ameriprise Financial Inc. now owns 203,170 shares of the biopharmaceutical company’s stock valued at $40,699,000 after purchasing an additional 155,795 shares during the last quarter. Finally, Royal London Asset Management Ltd. lifted its holdings in shares of Alnylam Pharmaceuticals by 86.7% during the third quarter. Royal London Asset Management Ltd. now owns 306,595 shares of the biopharmaceutical company’s stock valued at $54,303,000 after purchasing an additional 142,357 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Trading Down 2.4 %

Shares of NASDAQ ALNY opened at $148.50 on Friday. The firm’s 50-day moving average price is $153.99 and its 200-day moving average price is $167.80. The stock has a market capitalization of $18.70 billion, a price-to-earnings ratio of -41.71 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 12-month low of $143.52 and a 12-month high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.10. The firm had revenue of $439.72 million during the quarter, compared to analysts’ expectations of $439.38 million. During the same period last year, the company earned ($1.68) earnings per share. The business’s revenue for the quarter was up 31.2% compared to the same quarter last year. On average, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -4.54 EPS for the current fiscal year.

Analyst Ratings Changes

ALNY has been the subject of several recent research reports. Citigroup lowered their target price on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a “buy” rating for the company in a report on Friday, February 16th. StockNews.com upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday. Cantor Fitzgerald restated a “neutral” rating and issued a $165.00 price objective on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 20th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $235.00 target price on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 20th. Finally, The Goldman Sachs Group downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the stock from $230.00 to $173.00 in a research report on Friday, February 16th. Eight equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $216.12.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.